Hyperfine, Inc.
Hyperfine, Inc. (Nasdaq: HYPR) develops and commercializes portable, AI-powered, ultra-low-field magnetic resonance imaging technology for brain imaging. Its Swoop® Portable MR Imaging® System is designed to produce brain images in professional healthcare settings where conventional MRI is unavailable, impractical, or… From the company’s description.
Over the twelve months to Jun 30, 2026, Hyperfine, Inc. reported revenue of $16.54M, up 53.2% from a year earlier, and a net loss of $34.85M. Its operating margin was −203.3%, and operations used $27.07M in cash. In fiscal 2025, it reported revenue of $13.56M, up 5.2% from fiscal 2024, and a net loss of $35.57M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Hyperfine, Inc. does
In the company’s own words
Hyperfine, Inc. (Nasdaq: HYPR) develops and commercializes portable, AI-powered, ultra-low-field magnetic resonance imaging technology for brain imaging. Its Swoop® Portable MR Imaging® System is designed to produce brain images in professional healthcare settings where conventional MRI is unavailable, impractical, or difficult to access, including hospital intensive care units, emergency departments, clinics, and neurology offices. Customers include hospitals, office-based neurology practices, and international healthcare providers reached through distributors. The system combines a portable scanner with Optive AI™ image-processing software and is sold primarily with annual software, service, and support agreements. Hyperfine also offers PULSE, a subscription-based platform for Swoop users that provides research sequences, imaging data, and tools for exploring applications. The company’s commercial focus is on U.S. hospitals and neurology offices, alongside international markets. Founded in 2014, Hyperfine has one commercial product platform; its wholly owned subsidiary Liminal Sciences, founded in 2018, suspended its brain vital-signs development program in 2022. Its website is https://hyperfine.io.
Company details
- Sector
- Health Care
- Industry (SIC)
- Electromedical Apparatus
- Headquarters
- GUILFORD, CT
- Fiscal year end
- December
- CIK
- 1833769
- SIC
- 3845
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Hyperfine, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Hyperfine, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Hyperfine, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Hyperfine, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Hyperfine, Inc.'s last four quarterly filings that the numbers alone won't show?”